TBG Diagnostics Limited (TDL)
Website:
tbgbio.com/en |
|
Headquarters:
AU |
|
Company Type:
Small Business (1-10M TTM Revenue) |
TBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnotics kits, instruments and services.
Company Structure Picture
TDL is comprised of the following subsidiaries: Texas BioGene Inc. in USA, TBG Biotechnology Corp. in Taiwan, and TBG Biotechnology Inc. (Xiamen) in China. Each subsidiary is focused on different business or functions. Texas Biogene Inc. is the research center, TBG Biotechnology Corp. Taiwan, is focused on Transplant and Transfusion Genetics, and TBG Biotechnology (Xiamen) Inc. is focused on Infectious Disease, and Oncology.
History
Texas BioGene Inc (TBG) was founded in Texas, USA (1999), TBG is one of the leading providers of quality Human Leukocyte Antigen (HLA) Typing Kits for immune matching of bone marrow, cord blood and organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China.
In 2006, Medigen Biotechnology Corp. acquired TBG for its potential in PCR diagnostics and to complement its existing drug development pipelines. To take advantage of the rapid growth in IVD market within China, Medigen Biotechnology Corp. acquired Shanghai Haoyuan in 2007 for its diagnostic distribution channels and licenses in China. By combining the strengths in TBG and Haoyuan, a new generation of Blood Screening was developed and succesfully marketed in China. In 2012, Perkin Elmer decided to acquired Shanghai Haoyuan from Medigen Biotechnology Corp. as a way to enter the Blood Screening business in China. While China is still a rapidlly growing market for IVD, TBG re-established the TBG Biotechnoloyg Inc. (Xiamen) as its new China subsidiary. The intent of this China facility is to go beyond the current scope of products and to become a major IVD leader in China. In early 2016, Progen Pharmaceiticals has decided to acquire TBG I. and rename the company to TBG Diagnostics Limited (TDL).
Site | Badges | |
---|---|---|
TBG Diagnostics Limited (TDL) Weng Jiao Lu Xiamen Shi, Fujian Sheng, China | ||
TBG Diagnostics Limited (TDL) 237 Section 1, Datong Road , New Taipei City, 221 Taiwan | ||
TBG Diagnostics Limited (TDL) 635 Presidential Drive Richardson, TX, 75081 United States | ||
TBG Diagnostics Limited (TDL) 18 Little Collins Street Melbourne, VIC, 3004 Australia | ||
TBG Diagnostics Limited (TDL) 2806 Ipswich Road Darra, QLD, 4076 Australia | ||
TBG Diagnostics Limited (TDL) Unit 6, 138 Juliette Street , , Australia |
Get started
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.